Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

Hurvitz, SA; Hegg, R; Chung, WP; Im, SA; Jacot, W; Ganju, V; Chiu, JWY; Xu, BH; Hamilton, E; Madhusudan, S; Iwata, H; Altintas, S; Henning, JW; Curigliano, G; Perez-Garcia, JM; Kim, SB; Petry, V; Huang, CS; Li, W; Frenel, JS; Antolin, S; Yeo, WN; Bianchini, G; Loi, S; Tsurutani, J; Egorov, A; Liu, YL; Cathcart, J; Ashfaque, S; Cortes, J

Hurvitz, SA (通讯作者)，Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol Oncol, Los Angeles, CA 90095 USA.;Hurvitz, SA (通讯作者)，Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.

LANCET, 2023; 401 (10371): 105

Abstract

Background An improvement in progression-free survival was shown with trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positi......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索